Abbott India Ltd Share Price

Overview

Abbott India Ltd share price is currently ₹26,247.04, up by ₹250.94 (0.97%) from its previous closing price of ₹25,996.10. The share price has declined -5.26% over the past month and declined -19.13% over the past year. The stock's 52-week low and high are ₹24,744.49 and ₹32,529.33, respectively. Abbott India Ltd has a market capitalisation of ₹ 55,740.00 Cr. The share price was last updated on 26 Aug 2026, 03:29 PM IST.

Abbott India Ltd
Abbott India Ltd
ABBOTINDIA
 0.00
 250.94
0.97%
Healthcare
 0.00(%)1D

Updated: 26 Aug 2026, 03:29:59 pm IST

Market Data

Open Price

 26,119.82

Prev. Close

 25,996.10
 26,002.72

Day Low

 26,247.04

Day High

 24,744.49

52 Week Low

 32,529.33

52 Week High

HealthcarePharmaceuticals & Drugs
CategoryLarge Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

34.54

Sector PE

42.03

PB Ratio

11.75

Sector PB

5.83

EPS

759.85

Dividend Yield

2.53

Today's Volume

6.256 K

5 Day Avg. Volume

8.728 K

PEG Ratio

3.55

Market Cap.

₹ 55,740.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsSpecial Dividend of 1310% at ₹131/Share
24-Jul-202624-Jul-2026
DividendsFinal Dividend of 5250% at ₹525/Share
24-Jul-202624-Jul-2026
DividendsFinal Dividend of 4750% at ₹475/Share
25-Jul-202525-Jul-2025

Mutual Fund Ownership

Mutual Fund Holder
Jun 26
Shares held
Jul 26
Shares held
SBI Large & Midcap Fund - Regular Plan - IDCW3.08 Lac
3.08 Lac
no change
Axis Midcap Fund - Regular Plan - Growth1.63 Lac
1.63 Lac
no change
Canara Robeco Large and Mid Cap Fund - Regular Plan - Growth1.39 Lac
1.32 Lac
(4.49%)
Nippon India Multi Cap Fund - Growth1.27 Lac
1.27 Lac
no change
Nippon India Pharma Fund - Growth74.34 k
74.80 k
(0.62%)

About Abbott India Ltd 👋

Abbott India Limited is an India-based pharmaceutical company. The Company is involved in product development, manufacturing, sales, and customer service. It distributes products and solutions in multiple therapeutic categories, such as women's health, gastroenterology, cardiology, metabolic disorders and primary care. It operates in a single reportable business segment, which is Pharmaceuticals. The Company's products include Arachitol Nano, Digeraft, Influvac, Colospa, Duphalac, Librax, Creon, Duphaston, Prothiaden, Cremaffin, Duvadilan, Thyronorm, Cremaffin Plus, Ganaton, Udiliv, Digene, Heptral, Vertin, Zolfresh, Citrosoda UTI, Digene Insta On The Go, Digeraft tablet, Duphaston OD, Pneumoshield 14, Prothiaden Neu, Vonefi, Levesam, and LOBATE M Skin Cream, among others. The Company sells its products through independent distributors primarily within India.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Stock Reader

Stock Reader

11 Aug • 9:02 PM · SEBI-Registered Analyst

Bullish on Abbott India because it combines a strong portfolio of trusted brands

ABBOTINDIA
Leadership across multiple therapeutic categories and a consistently high-quality business model. The company has built a strong franchise in chronic and acute therapies, with 16 brands ranked #1 or #2 in their respective markets and several brands among the largest in the Indian pharmaceutical market. Abbott’s long-standing presence in India, extensive distribution network and strong brand equity create significant entry barriers. More importantly, the company has demonstrated consistent financial execution, with its FY2024-25 annual report highlighting a 10-year revenue CAGR of 9.3% and EBITDA CAGR of 16.9%. The long-term opportunity remains attractive as India’s healthcare spending, diagnosis rates and demand for quality medicines continue to rise. Abbott India is well positioned to benefit from these structural trends through its presence in areas such as women’s health, gastroenterology, metabolic disorders, CNS, vaccines and other specialty therapies. Its focus on premium, established brands provides pricing power and supports healthy margins and return ratios. The company also continues to strengthen its product portfolio and participate in growing healthcare segments. While valuation remains an important consideration, we believe the combination of strong brands, recurring demand, operating efficiency, balance-sheet strength and long-term healthcare growth makes Abbott India a compelling quality compounder for investors with a long-term horizon.

See More
Lovelesh Sharma

Lovelesh Sharma

11 Aug • 5:30 PM · SEBI-Registered Analyst

ABBOTINDIA
- Bullish Engulfing

ABBOTINDIA
- The chart shows a sharp prior upmove followed by consolidation around 27,535–28,020. Price is holding the lower end of the range, but the immediate hurdle is 28,020–28,135. A breakout above this zone can resume the upward momentum towards 28,660 and 29,410. Support is at 27,535, followed by 27,160. Holding 27,535 keeps the bullish structure intact, while a break below it would weaken the setup.

See More
SHUBINVESTS I SEBI RA

SHUBINVESTS I SEBI RA

4 Aug • 9:04 AM · SEBI-Registered Analyst

When Governance Breaks, Markets Remember: The Zee-SEBI Case Explained

Strong governance protects shareholder wealth. Transparent disclosures and ethical leadership matter as much as financial performance for long-term investing success. A company's biggest asset isn't always its land, factories, or cash. Sometimes, it's investor trust. SEBI's final order in the Zee Entertainment matter highlights a lesson every investor should remember. According to the regulator, company-owned assets were allegedly used to support promoter-linked entities without proper board approval, while the related information was not transparently disclosed in the company's annual reporting. The case reinforces that governance failures can become significant investment risks. The important takeaway is broader than a single company. When evaluating any business, don't stop at revenue growth, profits, or valuation. Ask deeper questions: • Does management treat minority shareholders fairly? • Are related-party transactions transparent? • Does the board function independently? • Are disclosures complete and timely? • Is promoter behaviour aligned with shareholder interests? History has repeatedly shown that poor governance eventually destroys value, even in businesses with strong brands. On the other hand, companies known for high governance standards often enjoy premium valuations because investors trust management to allocate capital responsibly. HDFC Bank

HDFCBANK
Infosys Tata Consultancy Services (TCS) Asian Paints
ASIANPAINT
Kotak Mahindra Bank Titan Company LTIMindtree Nestlé India Abbott India
ABBOTINDIA
These companies are often appreciated for transparent disclosures, disciplined capital allocation, and shareholder-focused management, though every investment still requires independent research. The real investment lesson: Financial statements tell you what happened. Corporate governance tells you how it happened. Over the long term, both matter equally.

See More
Saurab Jain

Saurab Jain

20 Jul • 3:33 PM · SEBI-Registered Analyst

ABB India Benefiting from Industrial Automation and Energy Transition

ABBOTINDIA
ABB India continues to strengthen its presence across electrification, industrial automation, robotics, and motion solutions, supported by rising investments in manufacturing, infrastructure, and renewable energy. Increasing adoption of smart factories, digital technologies, and energy-efficient systems provides long-term growth opportunities. The company’s diversified customer base across industries and focus on high-value engineering solutions enhance business resilience. However, fluctuations in industrial capital expenditure, raw material costs, project execution timelines, and global economic conditions remain key factors influencing revenue growth and overall financial performance. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes ***** must verify information before investing and consider their financial position & risk profile. please read full disclosure disclaimer in given link visit website www dot investmentcure dot com *****

See More
Vivek kumar

Vivek kumar

19 Jul • 6:01 PM · SEBI-Registered Analyst

88 stocks to trade ex-dividend/ex-bonus this week!

88 stocks to trade ex-dividend/ex-bonus this week! A total of 88 companies are scheduled to trade ex-dividend, ex-bonus, or ex-stock split during the week. Major names include Bharti Airtel, Hero MotoCorp, Abbott India, and Info Edge. Investors must hold these shares before their respective record dates to be eligible for the announced corporate benefits.

See More
Saurab Jain

Saurab Jain

9 Jul • 6:18 PM · SEBI-Registered Analyst

ABB India Benefits from Electrification, Automation and Infrastructure Demand

ABBOTINDIA
ABB India continues to strengthen its position through growing demand for electrification, industrial automation, robotics, motion, and energy-efficient solutions. The company is benefiting from increasing investments in manufacturing, data centers, railways, utilities, renewable energy, and smart infrastructure. Its focus on digital technologies, process automation, and high-value engineering solutions supports long-term growth while maintaining a strong balance sheet and healthy cash generation. Investors are closely monitoring order inflows, execution, margins, capacity expansion, and demand across industrial and infrastructure sectors as key indicators of the company’s operational performance. Disclaimer: Investments in securities are subject to market risks. This content is for educational and informational purposes only and should not be construed as investment advice or a recommendation to buy, sell, or hold any security.

See More

News & Events

Frequently Asked Questions

What is the share price of Abbott India Ltd?

What is the market cap of Abbott India Ltd?

Should I buy Abbott India Ltd stock now?

What is the 52 week high and low of Abbott India Ltd?

Is the Abbott India Ltd stock good to buy?

Is Abbott India Ltd a good buy for the long term?

Is Abbott India Ltd overvalued or undervalued?

What is the PE and PB ratio of Abbott India Ltd?

Start Now